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Background: Exposed to antipsychotic drugs (APDs), older individuals with dementing 
illness are at risk of cerebrovascular adverse effects (CVAE), including sudden death. 
Transient microvascular dysfunctions are known to occur in younger persons exposed 
to APDs; however, they seldom progress to CVAE, suggesting that APDs alone are 
insufficient for engendering this untoward effect. It is, therefore, believed that a preexis-
tent microvascular damage is necessary for CVAE to take place, but the exact nature of 
this lesion remains unclear. CNS small vessel disease (SVD) is a well-known age-related 
risk factor for strokes, dementia, and sudden death, which may constitute the initial 
CVAE-predisposing pathology. Therefore, we propose the two strikes CVAE paradigm, 
in which SVD represents the first strike, while exposure to APDs, the second. In this 
model, both strikes must be present for CVAE to take place, and the neuroimaging 
load of white matter hyperintensities may be directly proportional with the CVAE risk. To 
investigate this hypothesis at the molecular level, we focused on a seemingly unrelated 
phenomenon: both APDs and SVD were found protective against a similar repertoire 
of cancers and their spread to the brain (1–4). Since microRNA-29 has shown efficacy 
against the same malignancies and has been associated with small vessels pathology, 
we narrowed our search down to this miR, hypothesizing that the APDs mechanism of 
action includes miR-29 upregulation, which in turn facilitates the development of SVD.
aim: To assess whether miR-29 can be utilized as a peripheral blood biomarker for SVD 
and CVAE risk.
Method: We conducted a search of experimentally verified miR-29 target genes utilizing 
the public domain tools miRanda, RNA22 and Weizemann Institute of Science miRNA 
Analysis. We identified in total 67 experimentally verified target genes for miR-29 family, 
18 of which correlate with microvascular integrity and may be relevant for CVAE.
Conclusion: Upregulated microRNA-29 silences the expression of 18 genes connected 
with capillary stability, engendering a major vulnerability for SVD (first strike) which in turn 
increases the risk for CVAE after exposure to APDs (second strike).
Keywords: antipsychotic medications, stroke, VeGF, microrna-29, sirt-1, diabetes mellitus
Abbreviations: AD, Alzheimer’s disease; Ahr, aryl hydrocarbon receptor; APDs, antipsychotic drugs; CVAE, cerebrovascular 
adverse effects; DM, diabetes mellitus; DNAm, DNA methylation; EMPs, extracellular matrix proteins; MicroRNA (miR), 
microribonucleic acid; NPCs, neural precursor cells; PPAR-gamma, peroxisome proliferator-activated receptor gamma; SIRT-1, 
NAD-dependent deacetylase sirtuin-1; SVD, small vessel disease; T2DM, type 2 diabetes mellitus; VR, vascular rehabilitation; 
WMHs, white matter hyperintensities.
FiGUre 1 | the two strikes CVae hypothesis. The antitumor effects of 
overexpressed miR-29 destabilizes cerebral microvessels, contributing to 
SVD, the first CVAE strike manifested by WMHs. APD, antipsychotic drugs; 
CVAE, cerebrovascular adverse effects; SVD, small vessels disease; WMH, 
white matter hyperintensities; miR-29, microRNA-29 family.
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introdUCtion
Cerebrovascular adverse effects (CVAE) of antipsychotic drugs 
(APDs) were first noted in dementia clinical trials in 2001 
(5, 6). In 2004, the United Kingdom Committee on the Safety of 
Medicines issued a warning to physicians regarding the potential 
risk for stroke in elderly with dementia treated with risperidone 
or olanzapine. In 2005, the US Food and Drug administration 
undertook a meta-analysis of over 5,000 patients with dementia-
related psychosis and concluded that aripiprazole, olanzapine, 
quetiapine, and risperidone may be associated with CVAE (7). 
A Medicare cohort study, looking at typical and atypical antipsy-
chotics in over 22,000 patients age 65 and older, concluded that 
conventional antipsychotics were associated with a 37% higher 
mortality due to CVAE than the atypical ones (8). A recent study 
revised upward the risk of death in older adults with dementing 
illness treated with APDs (9).
Cerebrovascular adverse effects are rare events, which occur 
in older individuals with dementia shortly after the initiation of 
APD treatment. They are believed to be unrelated to the metabolic 
adverse effects, which develop over an extended period of time, 
although both may involve similar pathogenesis (10).
Transient cerebral small vessels lesions have been reported 
previously in younger individuals with schizophrenia during the 
early phase of APD treatment; however, they almost never pro-
gress to CVAE, suggesting that the APDs alone are insufficient for 
triggering these adverse effects (11). A preexistent, occult cerebral 
small vessel disease (SVD) is a likely predisposing factor as it may 
engender a background of microvascular instability upon which 
the addition of APDs could trigger CVAE. In our two strikes 
model, brain SVD [measured by the white matter hyperintensi-
ties (WMHs load)] comprises the first strike, while exposure to 
APDs the second. CVAE can only occur in the presence of both 
strikes (Figure 1).
Several studies have demonstrated that cerebral SVD alone 
increases the risk for strokes, cognitive impairment, and sudden 
death (12, 13). In addition, this condition is often associated with 
hypertension, atherosclerosis, or diabetes mellitus (DM), disor-
ders known to induce CNS microvascular lesions (14). Novel 
epigenetic studies have reported upregulation of microRNA-29 
in some cancers, DM, atherosclerosis, hypercholesterolemia, and 
normal aging, while downregulation of this miR characterizes 
Alzheimer’s disease (AD) (15–17).
Malignancies were demonstrated capable of hijacking 
microvascular cells and utilize them for tumorigenesis and 
metastatic spread. They accomplish this through cancer-
expressed biomolecules and oncogenes, which alter gene 
expressions to support cancer-related angiogenesis and micro-
vascular recruitment (18–20). The anti-malignancy action of 
miR-29 consists of directly silencing these genes, thus blocking 
the cell cycle entry of both tumor cells and the cells hijacked by 
tumors (primarily the endothelial cells and pericytes in brain 
microvessels). This action prevents cancer growth and spread 
but increases the risk of small vessels damage, as these cells must 
undergo frequent mitosis in order to maintain the integrity of 
capillary beds. For example, miR-29 was demonstrated to con-
trol the expression of NAD-dependent deacetylase sirtuin-1 
(SIRT-1) gene, vascular endothelial growth factor (VEGF) 
gene, and 16 genes coding for extracellular matrix proteins 
(EMPs), in charge of small vessels’ integrity. Overexpression 
of miR-29 may silence these genes, leading to microvascular 
lesions and SVD (21, 22) (Figure 2).
Antipsychotic drugs were reported to have therapeutic value 
in colorectal carcinoma, acute lymphoblastic leukemia, and the 
ovarian cancer, the same malignancies in which miR-29 was 
found beneficial (23–26). Furthermore, it was demonstrated 
that the antitumor actions of APDs rely on silencing the 
expression of SIRT-1 gene and/or altering DNA methylation, 
both of which are known properties of miR-29 (27) (Figure 3). 
Therefore, we suggest that APDs induce miR-29 overexpres-
sion, which in turn provides therapeutic benefit in these can-
cers but at the same time facilitates the development of SVD, 
the first CVAE strike. In addition, we present two potential 
biological markers of SVD and by extension of CVAE risk: a 
neuroimaging hallmark, WMH, and a peripheral blood marker, 
microRNA-29.
CereBraL sMaLL VesseL disease, 
tHe First CVae striKe
Cerebral SVD represents a group of age-related conditions, 
including deep brain infarcts, lacunar infarcts, microbleeds, and 
white matter lesions. These disorders have a common denomina-
tor: involvement of small CNS arteries, arterioles, capillaries, and 
small veins, increasing the risk of cognitive impairment and geri-
atric syndromes (28, 29). Recent data demonstrate that 25–30% 
of strokes are associated with SVD, but even in the absence of 
larger cerebrovascular accidents, SVD may result in cognitive 
decline, representing the most common cause of vascular and 
mixed dementias. The neuroimaging hallmark of SVD is WMHs 
FiGUre 2 | in the Cns, the astrocyte is the source of mir-29. In normal 
aging, miR-29 is overexpressed for neuroprotective purposes. In AD, 
astrocytes undergo early apoptosis, depressing the levels of miR-29, which 
may account for the neuronal aberrant entry into the cell cycle and 
subsequent apoptosis.
FiGUre 3 | mir-29 silences sirt-1, VeGF, and 16 other genes expressing eCM proteins, preventing cancer growth and metastasis by denying 
access to microvascular recruitment and angiogenesis necessary for spread. APDs exert antitumor effect against the same malignancies by silencing the 
SIRT-1 gene.
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frequently visualized on magnetic resonance imaging (MRI) in 
older persons (30).
Both genetic and epigenetic factors have been involved in the 
cerebral SVD, and its heritability is estimated at 55–80%, while 
epigenetic mechanisms described in its pathogenesis include 
methylation and posttranslational modifications, impairing the 
cell cycle and causing apoptosis of endothelial cells and pericytes 
(31, 32). A rare form of familial SVD, indistinguishable from the 
sporadic form, was described in association with impaired collagen 
type IV, one of the EMPs directly controlled by miR-29 (33, 34).
A recent, large epidemiologic study in SVD revealed that 
in elderly, the amount of WMHs on MRI was proportional to 
the increase in systolic blood pressure (BP) (35). Recent studies 
demonstrated that BP homeostasis is impacted negatively by a 
dysfunctional biomolecule, the peroxisome proliferator-activated 
receptor gamma (PPAR-gamma) found in the microvascular 
smooth muscle cells (36). Interestingly, PPAR-gamma agonists 
were recently shown to induce the expression of VEGF gene (a 
gene directly controlled by miR-29), promoting angiogenesis and 
tissue repair after myocardial infarctions (37). A recent study 
found miR-29 downregulation to protect against hypertension-
induced myocardial ischemia, while another study demonstrated 
the involvement of dysfunctional miR-29 in pulmonary hyper-
tension (38, 39). Moreover, miR-29a was associated with age-
induced aneurysm formation and was found to be overexpressed 
in cultured senescent endothelial cells (40, 41). Taken together, 
these data suggest that miR-29 plays a key role in hypertension-
associated pathology, which can lead to SVD.
Antipsychotic drugs were demonstrated to engender transient 
microvascular impairment in younger individuals with schizo-
phrenia during the early phase of treatment (11). These vascular 
changes, even though insufficient to trigger CVAE in adults with-
out SVD, suggest an association between APDs and brain micro-
vascular dysfunctions. Indeed, studies in rodents documented 
cerebral small vessel lesions in APDs-exposed animals (42, 43).
In cancer and AD, microRNA-29 was demonstrated to alter 
DNA methylation (DNAm), affecting expression of many genes 
4Sfera et al. Antipsychotics, Metabolic Disorders, Cerebrovascular Accidents, and miR-29
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(44, 45). While silencing cancer-related genes, this epigenetic 
mechanism may also engender microvascular damage (46, 47). 
Interestingly, some APDs were associated with increased DNAm 
in various areas of the CNS, suggesting that APDs and miR-29 
may share a common mechanism of action. In this respect, a 
recent preclinical study demonstrates that olanzapine induces 
cerebellar and hippocampal DNAm, while another study showed 
that haloperidol upregulates DNAm in the striatum (48, 49). 
Interestingly, schizophrenia was associated with de-methylation 
of various gene promoters; a recent twin study documented 
the hypomethylation of ST6GALNAC1 gene promoter in the 
schizophrenia-affected twin, suggesting that a DNAm deficit may 
play a role in the pathogenesis of this disorder (50).
Studies in normal aging describe the “epigenetic clock” as 
measuring DNAm at specific genomic sites. The amount of DNAm 
in these areas was found to be highly correlated with the human 
chronological age (51). Since SVD occurs in older individuals and 
aging is proportional to DNAm and miR-29 expression, the “epi-
genetic clock” may measure the degree of microvascular damage. 
Indeed, in pluripotent stem cells, low levels of miR-29 were shown 
to induce DNA demethylation, bringing these cells a step closer 
to the embryonic stem cells (in which DNAm is almost nil) (52).
In regard to miR-29 in AD, an apparent paradox has been 
described: this miR is overexpressed in normal aging but under-
expressed in age-related pathologies, including AD. For example, 
dementia studies report that AD patients present with low levels 
of miR-29 and that adding recombinant pre-miR-29b to the 
therapeutic regimen could be beneficial (15, 53). In addition, 
several studies demonstrated that miR-29 is neuroprotective and 
that its loss may, at least in part, account for the pathogenesis of 
AD (54). However, seen from another angle, the low miR-29 level 
in AD may not represent a paradox at all. As astrocytes secrete 
this miR exclusively and astrocytes are known to undergo early 
apoptosis in AD, the low levels of this miR may simply reflect the 
loss of its source (55) (Figure 2).
In addition, miR-29 is a known blocker of cellular entry into 
the cell cycle, and its protective role in the brain may include 
preventing the neurons, from attempting division. Indeed, in 
AD, neurons were demonstrated to attempt cell cycle entry in an 
aberrant manner, undergoing apoptosis as they lack the cellular 
machinery to complete this process (56, 57). Preclinical studies 
demonstrate that blocking miR-29 induces post-mitotic cells 
(including adult cardiomyocytes) to engage aberrantly in division 
(58). Indeed, one study revealed that the unopposed cyclin D2, 
a direct target of microRNA-29a, induces post-mitotic cells to 
attempt mitosis (59). We surmise that the early loss of astrocytes 
in AD accounts for miR-29 depletion, which in turn disinhibits 
cyclin D2, triggering neuronal apoptosis following unsuccessful 
attempts at completing the cell cycle.
CVae and MetaBoLiC adVerse 
eFFeCts oF apds: saMe 
patHoGenesis, diFFerent tiMinG?
In older individuals with dementia, CVAE are rare untoward 
events associated with the early phase of treatment with APDs. 
In spite of the fact that they are considered unrelated to the 
metabolic adverse effects, which are known to occur later in the 
treatment, they may share an identical pathogenesis.
It is well known that the incidence of cancer, metabolic dis-
orders, and dementias increases with age. As these conditions 
frequently affect the CNS capillary bed, the genes associated with 
cerebral microvascular integrity may play a crucial role in their 
pathogenesis. Moreover, since upregulation of micro-RNA-29 
occurs in normal aging and this miR blocks the expression of 
SIRT-1, VEGF, and several EMPs, it may be crucial to these 
pathologies.
Several new studies demonstrated that SIRT-1 gene plays a 
key role in the energy balance, as it functions as a “metabolic 
sensor,” modulating cellular responses to the energy availability 
(60). As some APDs silence SIRT-1 gene, this gene may represent 
the missing link between the CVAE pathogenesis and that of 
metabolic adverse effects of APDs. Indeed, it was demonstrated 
that SIRT-1, a NAD+-dependent histone deacetylase, regulates 
the glucose and lipid metabolism by deacetylating several key 
metabolic effectors (61). Silencing the expression of SIRT-1 
was demonstrated to result in insulin resistance, type 2 diabetes 
mellitus (T2DM), and dyslipidemias, which are all recognized 
adverse effects of atypical APDs (17, 62). In addition, blocking 
the expression of VEGF was associated with hypercholester-
olemia and insulin resistance (63–65). As miR-29 upregulation 
accompanies the same metabolic disorders, it suggests that (1) 
miR-29 overexpression triggers metabolic disorders by silencing 
SIRT-1 and VEGF genes and (2) APDs upregulate miR-29 as part 
of their mechanism of action, thus enabling the development of 
metabolic adverse effects.
In addition to regulating glucose metabolism at the level of 
insulin-target cells, preclinical studies documented that VEGF 
and SIRT-1 genes act directly on pancreatic beta cells, facilitat-
ing insulin release (66, 67). Moreover, a preclinical study dem-
onstrated a direct link between miR-29 and pancreatic insulin 
release, further connecting this miR with the metabolic adverse 
effects of APDs (68). Furthermore, miR-29-induced cell cycle 
blockade may affect negatively the blood–brain barrier (BBB), 
especially at the level of endothelial cells and pericytes. As these 
cells express glucose transporters that help shuttle glucose to the 
brain, their dysfunction would interfere with this process, further 
impairing the CNS metabolism (69). In addition to metabolic 
disorders, breaches of the BBB were associated with increased 
risk of SVD, stroke, and AD (70–72). Furthermore, since both 
pericytes and endothelial cells were demonstrated to secrete 
VEGF, a dysfunction of these cells may impair VEGF synthesis 
and result in further microvascular damage (18, 73).
Metabolic disorders, including T2DM, were found comorbid 
with several cancers among which are the acute lymphoblastic 
leukemia and colorectal and ovarian cancer, the same malignan-
cies in which miR-29 and APDs provide therapeutic benefit, sug-
gesting yet another link between metabolic disorders, APDs and 
miR-29 (74–76) (Figure  2). Moreover, in colorectal carcinoma 
chlorpromazine, clozapine and olanzapine were documented to 
inhibit SIRT-1 gene expression, a gene directly controlled by miR-
29, and in acute lymphoblastic leukemia, phenothiazines were 
shown to block T cells’ division, utilizing a property of miR-29. 
taBLe 1 | the beneficial effect of antipsychotic drugs and microrna-29 
by cancer type with references.
antipsychotic drugs 
(apds)
Cancer type references 
apds
references 
microrna-29
Chlorpromazine Colorectal (26) (2)
Clozapine/olanzapine Non-small cell lung (23) (79)
Phenothiazines Acute lymphoblastic 
leukemia
(25) (4)
Thioridazine Ovarian (24) (3)
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These data suggest once more that miR-29 may be upregulated 
by APDs with metabolic and microvascular consequences (43) 
(Table 1). Interestingly, miR-29c was found to be downregulated 
in the prefrontal cortex of patients with schizophrenia (77, 78).
Recent studies demonstrated that miR-29 has the capability of 
blocking melatonin secretion from the pineal gland by binding 
to melatonin-1 receptors. As melatonin is a powerful inhibitor 
of endothelial apoptosis, blocking this hormone may further 
predispose to CNS microvascular damage (40).
Taken together, these data are in line with our hypothesis 
linking miR-29 with SVD and metabolic adverse effects of APDs.
disCUssion
Aggressive behaviors in older patients with dementia require, at 
times, treatment with APDs to prevent injuries to self or others. 
However, clinicians often avoid these helpful drugs, as they were 
associated with CVAE. The hypothesis presented here may allow 
identification of CVAE vulnerable individuals via biomarkers, 
such as WMHs load and/or high levels of exosomal microRNA-29 
in peripheral blood. Aside from presenting putative markers, this 
hypothesis points to therapeutic targets with potential to restore 
the function of the brain microvascular bed. Indeed, vascular 
rehabilitation (VR) is an emerging new field, attempting to 
resuscitate the integrity of small vessels after strokes, congestive 
heart failure, or metabolic disorders. As microRNA-29 and the 
genes it controls are crucial for endothelial health, they represent 
promising treatment targets for VR (40, 80). Moreover, receptor 
agonists, mimicking the gene products suppressed by miR-29, 
may restore brain microvascular function or prevent further loss.
sirt-1 agonists
The addition of SIRT-1 agonist, resveratrol, to elderly individuals 
on APDs may offer protection against SVD. In cardiac failure, 
resveratrol was demonstrated to augment the heart function, 
probably by restoring small vessels’ function (81). Other SIRT-1 
agonists were found beneficial in T2DM-associated microvascu-
lar damage. For example, SRT1720 was demonstrated to augment 
microvascular stability and promote wound healing (82, 83). 
A recent preclinical study revealed that directly lowering miR-29 
was beneficial for reversing T2DM and hypercholesterolemia (17).
VeGF agonists
Proliferator-activated receptor gamma agonists, known for their 
ability to induce the expression of VEGF, may provide additional 
benefit in the prevention of SVD and CVAE (84). Interestingly, 
a nuclear transcription factor, aryl hydrocarbon receptor (Ahr), 
a biomolecule directly controlled by miR-29, was documented 
to upregulate the expression of the VEGF gene in the lung (85). 
Natural PPAR-gamma agonists, including honokiol, amorfrutin 
1, amorfrutin B, amorphastilbol, were demonstrated capable of 
improving metabolic parameters in animal models of T2DM-
associated microvascular damage (86).
Melatonin receptor agonists
Currently used in sleep disorders, these compounds were shown 
effective in preserving microvascular integrity and have been sug-
gested in the treatment of cerebral ischemia (87). MicroRNA-29b 
is known to downregulate melatonin-1 receptors, possibly induc-
ing cerebral small vessel lesions (88). As part of the treatment 
regimen in older individuals on APDs, melatonin may prevent or 
even restore the integrity of cerebral small vessels.
An interesting concept has been advanced lately regarding 
the role of adult neurogenesis in various areas of the brain vis-
à-vis microvascular integrity and metabolism (89). Interestingly, 
disruptions of adult neurogenesis were described in depression, 
anxiety, schizophrenia, and neurodegenerative disorders (90). In 
addition, it is known that some psychotropic drugs augment the 
proliferation of neural precursor cells (NPCs) and their differen-
tiation into new neurons (90). As a “metabolic sensor,” SIRT-1 
gene was demonstrated to play a key role in adult neurogen-
esis by directing resources to the energy-consuming NPCs (91). 
Therefore, augmenting SIRT-1 via agonists, such as resveratrol or 
resveratrol-like agents, may be beneficial for brain neurogenera-
tive niches. For example, the hypothalamic neurogenesis zone is 
believed to supply new neurons to the medio-basal hypothalamus, 
an area in charge of metabolism (92–94). Facilitating neuronal 
replacement in this high wear and tear niche may prove beneficial 
for insulin/leptin resistance.
A frequently forgotten population are the older individuals 
with a life-long history of schizophrenia who develop late-life 
dementia. Because of improved medical care, individuals with 
schizophrenia live longer and were shown to be at higher risk 
of late-life dementia compared to the general population (95). 
Therapeutic guidelines for safe treatment of elderly with chronic 
schizophrenia and new onset dementia represent an unmet 
medical need, which will become more prominent along with 
the demographics of aging population. At present, there are no 
evidence-based data on the incidence of CVAE risk in this popu-
lation. Moreover, there is no clear answer to the question: Which 
individuals require low APDs dosage in order to avoid CVAE 
and which need and can tolerate higher doses to avoid relapses 
into psychosis and/or aggressive behavior? In our opinion, bio-
logical markers, including WMHs and miR-29, may be valuable 
diagnostic tools for assessing the CVAE risk in the elderly with 
schizophrenia and dementia.
ConCLUsion
The benefits of elucidating the molecular underpinnings of CVAE 
and metabolic adverse effects of APDs extend beyond the field of 
psychiatry and psychopharmacology. Metabolic disorders, cancer, 
and stroke affect a large percentage of the geriatric population, 
6Sfera et al. Antipsychotics, Metabolic Disorders, Cerebrovascular Accidents, and miR-29
Frontiers in Endocrinology | www.frontiersin.org August 2016 | Volume 7 | Article 122
and their pathogenesis is intertwined with the mechanism of 
action of APDs. The molecular mechanisms of these conditions 
superimposed on a background of aging engender a continuum 
with blurred boundaries between physiology and pathology. 
Epigenetics of APDs may represent the catalyst for shedding 
more light into specific areas where further advances are possible, 
including SVD, cancer, and metabolism.
From the epigenetic perspective, APDs are molecules pertain-
ing to the environment, which trigger specific responses in the 
body. These responses consist of expression or suppression of 
genes via epigenetic tools, including DNAm and microRNAs. In 
the case of APDs, these mechanisms may avert cancer at the price 
of SVD. It is up to future research to provide answers to the fol-
lowing questions: (1) Is it possible to augment the function of the 
cerebral microvascular bed without triggering cancer? (2) Can 
agonists of SIRT-1 or VEGF solve this problem without lifting the 
cell cycle blockade and unleashing malignancies?
aUtHor ContriBUtions
All authors listed have made substantial, direct, and intellectual 
contribution to the work and approved it for publication.
reFerenCes
1. Rahmathulla G, Toms SA, Weil RJ. The molecular biology of brain metastasis. 
J Oncol (2012) 2012:723541. doi:10.1155/2012/723541 
2. Wang B, Li W, Liu H, Yang L, Liao Q, Cui S, et al. miR-29b suppresses tumor 
growth and metastasis in colorectal cancer via downregulating Tiam1 expres-
sion and inhibiting epithelial-mesenchymal transition. Cell Death Dis (2014) 
5(7):e1335. doi:10.1038/cddis.2014.304 
3. Teng Y, Zhang Y, Qu K, Yang X, Fu J, Chen W, et al. MicroRNA-29B (miR-29b) 
regulates the Warburg effect in ovarian cancer by targeting AKT2 and AKT3. 
Oncotarget (2015) 6(38):40799–814. doi:10.18632/oncotarget.5695 
4. Oliveira LH, Schiavinato JL, Fráguas MS, Lucena-Araujo AR, Haddad  R, 
Araújo AG, et  al. Potential roles of microRNA-29a in the molecular 
pathophysiology of T-cell acute lymphoblastic leukemia. Cancer Sci (2015) 
106(10):1264–77. doi:10.1111/cas.12766 
5. Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular 
events in dementia trials. CMAJ (2002) 167(11):1269–70. 
6. Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular 
events in dementia trials. CMAJ (2004) 170(9):1395. doi:10.1503/cmaj.1040539 
7. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic 
drug treatment for dementia: meta-analysis of randomized placebo-controlled 
trials. JAMA (2005) 294(15):1934–43. doi:10.1001/jama.294.15.1934 
8. Wang PS, Schneeweiss S, Avorn J, Fischer MA, Mogun H, Solomon DH, et al. 
Risk of death in elderly users of conventional vs. atypical antipsychotic med-
ications. N Engl J Med (2005) 353(22):2335–41. doi:10.1056/NEJMoa052827 
9. Maust DT, Kim HM, Seyfried LS, Chiang C, Kavanagh J, Schneider LS, et al. 
Antipsychotics, other psychotropics, and the risk of death in patients with 
dementia: number needed to harm. JAMA Psychiatry (2015) 72(5):438–45. 
doi:10.1001/jamapsychiatry.2014.3018 
10. Balf G, Stewart TD, Whitehead R, Baker RA. Metabolic adverse events in 
patients with mental illness treated with antipsychotics: a primary care 
perspective. Prim Care Companion J Clin Psychiatry (2008) 10(1):15–24. 
doi:10.4088/PCC.v10n0104 
11. Szeszko PR, Robinson DG, Ikuta T, Peters BD, Gallego JA, Kane J, et al. White 
matter changes associated with antipsychotic treatment in first-episode 
psychosis. Neuropsychopharmacology (2014) 39(6):1324–31. doi:10.1038/
npp.2013.288 
12. Staals J, Makin SD, Doubal FN, Dennis MS, Wardlaw JM. Stroke subtype, vas-
cular risk factors, and total MRI brain small-vessel disease burden. Neurology 
(2014) 83(14):1228–34. doi:10.1212/WNL.0000000000000837 
13. van Norden AG, de Laat KF, Gons RA, van Uden IW, van Dijk EJ, van 
Oudheusden LJ, et  al. Causes and consequences of cerebral small vessel 
disease. The RUN DMC study: a prospective cohort study. Study rationale 
and protocol. BMC Neurol (2011) 11:29. doi:10.1186/1471-2377-11-29 
14. Khan U, Porteous L, Hassan A, Markus HS. Risk factor profile of cerebral 
small vessel disease and its subtypes. J Neurol Neurosurg Psychiatry (2007) 
78(7):702–6. doi:10.1136/jnnp.2006.103549 
15. Hébert SS, Horré K, Nicolaï L, Papadopoulou AS, Mandemakers W, 
Silahtaroglu  AN, et  al. Loss of microRNA cluster miR-29a/b-1 in sporadic 
Alzheimer’s disease correlates with increased BACE1/β-secretase expression. 
Proc Natl Acad Sci U S A (2008) 105(17):6415–20. doi:10.1073/pnas.0710263105 
16. Ślusarz A, Pulakat L. The two faces of miR-29. J Cardiovasc Med (Hagerstown) 
(2015) 16(7):480–90. doi:10.2459/JCM.0000000000000246 
17. Kurtz CL, Fannin EE, Toth CL, Pearson DS, Vickers KC, Sethupathy P. 
Inhibition of miR-29 has a significant lipid-lowering benefit through sup-
pression of lipogenic programs in liver. Sci Rep (2015) 5:12911. doi:10.1038/
srep12911 
18. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 
(2005) 69(Suppl 3):4–10. doi:10.1159/000088478 
19. Wang Z, Chen W. Emerging roles of SIRT1 in cancer drug resistance. Genes 
Cancer (2013) 4(3–4):82–90. doi:10.1177/1947601912473826 
20. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer 
progression. J Cell Biol (2012) 196(4):395–406. doi:10.1083/jcb.201102147 
21. Smirnova L, Gräfe A, Seiler A, Schumacher S, Nitsch R, Wulczyn FG. Regulation 
of miRNA expression during neural cell specification. Eur J Neurosci (2005) 
21(6):1469–77. doi:10.1111/j.1460-9568.2005.03978.x 
22. Brown WR, Thore CR. Review: cerebral microvascular pathology in aging 
and neurodegeneration. Neuropathol Appl Neurobiol (2011) 37(1):56–74. 
doi:10.1111/j.1365-2990.2010.01139.x 
23. Yin YC, Lin CC, Chen TT, Chen JY, Tsai HJ, Wang CY, et al. Clozapine induces 
autophagic cell death in non-small cell lung cancer cells. Cell Physiol Biochem 
(2015) 35(3):945–56. doi:10.1159/000369751 
24. Park MS, Dong SM, Kim BR, Seo SH, Kang S, Lee EJ, et al. Thioridazine inhib-
its angiogenesis and tumor growth by targeting the VEGFR-2/PI3K/mTOR 
pathway in ovarian cancer xenografts. Oncotarget (2014) 5(13):4929–34. 
doi:10.18632/oncotarget.2063 
25. Gutierrez A, Pan L, Groen RW, Baleydier F, Kentsis A, Marineau J, 
et  al. Phenothiazines induce PP2A-mediated apoptosis in T cell acute 
lymphoblastic leukemia. J Clin Invest (2014) 124(2):644–55. doi:10.1172/ 
JCI65093 
26. Lee WY, Lee WT, Cheng CH, Chen KC, Chou CM, Chung CH, et  al. 
Repositioning antipsychotic chlorpromazine for treating colorectal cancer 
by inhibiting sirtuin 1. Oncotarget (2015) 6(29):27580–95. doi:10.18632/
oncotarget.4768 
27. Xu L, Xu Y, Jing Z, Wang X, Zha X, Zeng C, et al. Altered expression pattern 
of miR-29a, miR-29b and the target genes in myeloid leukemia. Exp Hematol 
Oncol (2014) 3:17. doi:10.1186/2162-3619-3-17 
28. Rincon F, Wright CB. Current pathophysiological concepts in cerebral small 
vessel disease. Front Aging Neurosci (2014) 6:24. doi:10.3389/fnagi.2014.00024 
29. Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical 
characteristics to therapeutic challenges. Lancet Neurol (2010) 9(7):689–701. 
doi:10.1016/S1474-4422(10)70104-6 
30. Wardlaw JM, Valdés Hernández MC, Muñoz-Maniega S. What are white 
matter hyperintensities made of? Relevance to vascular cognitive impairment. 
J Am Heart Assoc (2015) 4(6):e001140. doi:10.1161/JAHA.114.001140 
31. Simpson JE, Hosny O, Wharton SB, Heath PR, Holden H, Fernando MS, 
et  al. Microarray RNA expression analysis of cerebral white matter lesions 
reveals changes in multiple functional pathways. Stroke (2009) 40:369–75. 
doi:10.1161/STROKEAHA.108.529214 
32. Atwood LD, Wolf PA, Heard-Costa NL, Massaro JM, Beiser A, D’Agostino RB, 
et al. Genetic variation in white matter hyperintensity volume in the Framingham 
Study. Stroke (2004) 35:1609–13. doi:10.1161/01.STR.0000129643.77045.10 
7Sfera et al. Antipsychotics, Metabolic Disorders, Cerebrovascular Accidents, and miR-29
Frontiers in Endocrinology | www.frontiersin.org August 2016 | Volume 7 | Article 122
33. Choi JC. Genetics of cerebral small vessel disease. J Stroke (2015) 17(1):7–16. 
doi:10.5853/jos.2015.17.1.7 
34. Joutel A, Faraci FM. Cerebral small vessel disease (SVD): insights and oppor-
tunities from mouse models of collagen IV-related SVD and CADASIL. Stroke 
(2014) 45(4):1215–21. doi:10.1161/STROKEAHA.113.002878 
35. Abraham HM, Wolfson L, Moscufo N, Guttmann CR, Kaplan RF, White WB. 
Cardiovascular risk factors and small vessel disease of the brain: blood pres-
sure, white matter lesions, and functional decline in older persons. J Cereb 
Blood Flow Metab (2016) 36(1):132–42. doi:10.1038/jcbfm.2015.121 
36. Halabi CM, Beyer AM, de Lange WJ, Keen HL, Baumbach GL, Faraci FM, et al. 
Interference with PPAR gamma function in smooth muscle causes vascular 
dysfunction and hypertension. Cell Metab (2008) 7(3):215–26. doi:10.1016/ 
j.cmet.2007.12.008 
37. Chintalgattu V, Harris GS, Akula SM, Katwa LC. PPAR-gamma agonists induce 
the expression of VEGF and its receptors in cultured cardiac myofibroblasts. 
Cardiovasc Res (2007) 74(1):140–50. doi:10.1016/j.cardiores.2007.01.010 
38. Ye Y, Hu Z, Lin Y, Zhang C, Perez-Polo JR. Downregulation of microRNA-29 
by antisense inhibitors and a PPAR-gamma agonist protects against myo-
cardial ischaemia-reperfusion injury. Cardiovasc Res (2010) 87(3):535–44. 
doi:10.1093/cvr/cvq053 
39. Cushing L, Costinean S, Xu W, Jiang Z, Madden L, Kuang P, et al. Disruption 
of miR-29 leads to aberrant differentiation of smooth muscle cells selectively 
associated with distal lung vasculature. PLoS Genet (2015) 11(5):e1005238. 
doi:10.1371/journal.pgen.1005238 
40. Dimmeler S, Nicotera P. MicroRNAs in age-related diseases. EMBO Mol Med 
(2013) 5(2):180–90. doi:10.1002/emmm.201201986 
41. Boon RA, Seeger T, Heydt S, Fischer A, Hergenreider E, Horrevoets AJ, et al. 
MicroRNA-29 in aortic dilation: implications for aneurysm formation. Circ 
Res (2011) 109:1115–9. doi:10.1161/CIRCRESAHA.111.255737 
42. Elmorsy E, Elzalabany LM, Elsheikha HM, Smith PA. Adverse effects of 
antipsychotics on micro-vascular endothelial cells of the human blood-brain 
barrier. Brain Res (2014) 1583:255–68. doi:10.1016/j.brainres.2014.08.011 
43. Elmorsy E, Smith PA. Bioenergetic disruption of human micro-vascular 
endothelial cells by antipsychotics. Biochem Biophys Res Commun (2015) 
460(3):857–62. doi:10.1016/j.bbrc.2015.03.122 
44. Morita S, Horii T, Kimura M, Ochiya T, Tajima S, Hatada I. miR-29 represses 
the activities of DNA methyltransferases and DNA demethylases. Int J Mol Sci 
(2013) 14(7):14647–58. doi:10.3390/ijms140714647 
45. Lu H, Liu X, Deng Y, Qing H. DNA methylation, a hand behind neurodegener-
ative diseases. Front Aging Neurosci (2013) 5:85. doi:10.3389/fnagi.2013.00085 
46. Lin SH, Wang J, Saintigny P, Wu CC, Giri U, Zhang J, et al. Genes suppressed 
by DNA methylation in non-small cell lung cancer reveal the epigenetics 
of epithelial-mesenchymal transition. BMC Genomics (2014) 15:1079. 
doi:10.1186/1471-2164-15-1079 
47. Raina A, Zhao X, Bressler J, Gottesman RF, Grove ML, Guan W, et  al. 
Abstract MP99: cerebral small vessel disease and the epigenetic clock: the 
Atherosclerosis Risk in Communities Study. Circulation (2016) 133:AM99. 
48. Melka MG, Laufer BI, McDonald P, Castellani CA, Rajakumar N, 
O’Reilly R, et al. The effects of olanzapine on genome-wide DNA methyla-
tion in the hippocampus and cerebellum. Clin Epigenetics (2014) 6(1):1. 
doi:10.1186/1868-7083-6-1 
49. Li J, Guo Y, Schroeder FA, Youngs RM, Schmidt TW, Ferris C, et al. Dopamine 
D2-like antagonists induce chromatin remodeling in striatal neurons through 
cyclic AMP-protein kinase A and NMDA receptor signaling. J Neurochem 
(2004) 90(5):1117–31. doi:10.1111/j.1471-4159.2004.02569.x 
50. Dempster EL, Pidsley R, Schalkwyk LC, Owens S, Georgiades A, Kane F, et al. 
Disease-associated epigenetic changes in monozygotic twins discordant for 
schizophrenia and bipolar disorder. Hum Mol Genet (2011) 20(24):4786–96. 
doi:10.1093/hmg/ddr416 
51. Horvath S. DNA methylation age of human tissues and cell types. Genome Biol 
(2013) 14(10):R115. doi:10.1186/gb-2013-14-10-r115 
52. Hysolli E, Tanaka Y, Su J, Kim KY, Zhong T, Janknecht R, et al. Regulation 
of the DNA methylation landscape in human somatic cell reprogramming 
by the miR-29 family. Stem Cell Reports (2016) 7(1):43–54. doi:10.1016/j.
stemcr.2016.05.014 
53. Pereira PA, Tomás JF, Queiroz JA, Figueiras AR, Sousa F. Recombinant 
pre-miR-29b for Alzheimer’s disease therapeutics. Sci Rep (2016) 6:19946. 
doi:10.1038/srep19946 
54. Roshan R, Shridhar S, Sarangdhar MA, Banik A, Chawla M, Garg M, et al. 
Brain-specific knockdown of miR-29 results in neuronal cell death and ataxia 
in mice. RNA (2014) 20(8):1287–97. doi:10.1261/rna.044008.113 
55. Rodríguez-Arellano JJ, Parpura V, Zorec R, Verkhratsky A. Astrocytes in 
physiological aging and Alzheimer’s disease. Neuroscience (2016) 323:170–82. 
doi:10.1016/j.neuroscience.2015.01.007 
56. Bonda DJ, Lee H, Kudo W, Zhu X, Smith MA, Lee H. Pathological implications 
of cell cycle re-entry in Alzheimer disease. Expert Rev Mol Med (2010) 12:e19. 
doi:10.1017/S146239941000150X 
57. Arendt T, Brückner MK. Linking cell-cycle dysfunction in Alzheimer’s disease 
to a failure of synaptic plasticity. Biochim Biophys Acta (2007) 1772(4):413–21. 
doi:10.1016/j.bbadis.2006.12.005 
58. Ahuja P, Sdek P, Maclellan WR. Cardiac myocyte cell cycle control in develop-
ment, disease and regeneration. Physiol Rev (2007) 87(2):521–44. doi:10.1152/
physrev.00032.2006 
59. Cao X, Wang J, Wang Z, Du J, Yuan X, Huang W, et al. MicroRNA profiling 
during rat ventricular maturation: a role for miR-29a in regulating cardio-
myocyte cell cycle re-entry. FEBS Lett (2013) 587(10):1548–55. doi:10.1016/j.
febslet.2013.01.075 
60. Guarani V, Potente M. SIRT1 – a metabolic sensor that controls blood 
vessel growth. Curr Opin Pharmacol (2010) 10(2):139–45. doi:10.1016/j.
coph.2010.01.001 
61. Kitada M, Koya D. SIRT1 in type 2 diabetes: mechanisms and therapeutic poten-
tial. Diabetes Metab J (2013) 37(5):315–25. doi:10.4093/dmj.2013.37.5.315 
62. Cao Y, Jiang X, Ma H, Wang Y, Xue P, Liu Y. SIRT1 and insulin resis-
tance. J Diabetes Complications (2016) 30(1):178–83. doi:10.1016/j.
jdiacomp.2015.08.022 
63. Yacoub R, Lee K, He JC. The role of SIRT1 in diabetic kidney disease. Front 
Endocrinol (2014) 5:166. doi:10.3389/fendo.2014.00166 
64. Arnold N, Koppula PR, Gul R, Luck C, Pulakat L. Regulation of cardiac 
expression of the diabetic marker microRNA miR-29. PLoS One (2014) 
9(7):e103284. doi:10.1371/journal.pone.0103284 
65. Hagberg CE, Mehlem A, Falkevall A, Muhl L, Fam BC, Ortsäter H, et  al. 
Targeting VEGF-B as a novel treatment for insulin resistance and type 2 
diabetes. Nature (2012) 490(7420):426–30. doi:10.1038/nature11464 
66. Brissova M, Shostak A, Shiota M, Wiebe PO, Poffenberger G, Kantz J, et al. 
Pancreatic islet production of vascular endothelial growth factor – a is essen-
tial for islet vascularization, revascularization, and function. Diabetes (2006) 
55(11):2974–85. doi:10.2337/db06-0690 
67. Luu L, Dai FF, Prentice KJ, Huang X, Hardy AB, Hansen JB, et al. The loss of Sirt1 
in mouse pancreatic beta cells impairs insulin secretion by disrupting glucose 
sensing. Diabetologia (2013) 56(9):2010–20. doi:10.1007/s00125-013-2946-5 
68. Pullen TJ, da Silva Xavier G, Kelsey G, Rutter GA. miR-29a and miR-29b 
contribute to pancreatic beta-cell-specific silencing of monocarboxylate 
transporter 1 (Mct1). Mol Cell Biol (2011) 31(15):3182–94. doi:10.1128/
MCB.01433-10 
69. Lee WL, Klip A. Shuttling glucose across brain microvessels, with a little help 
from GLUT1 and AMP kinase. Focus on “AMP kinase regulation of sugar 
transport in brain capillary endothelial cells during acute metabolic stress”. Am 
J Physiol Cell Physiol (2012) 303(8):C803–5. doi:10.1152/ajpcell.00241.2012 
70. Liu S, Agalliu D, Yu C, Fisher M. The role of pericytes in blood-brain 
barrier function and stroke. Curr Pharm Des (2012) 18(25):3653–62. 
doi:10.2174/138161212802002706 
71. van de Haar HJ, Burgmans S, Jansen JF, van Osch MJ, van Buchem MA, 
Muller M, et al. Blood-brain barrier leakage in patients with early Alzheimer 
disease. Radiology (2016) 31:152244. doi:10.1148/radiol.2016152244 
72. Schreiber S, Bueche CZ, Garz C, Braun H. Blood brain barrier breakdown 
as the starting point of cerebral small vessel disease? – new insights from a 
rat model. Exp Transl Stroke Med (2013) 5(1):4. doi:10.1186/2040-7378-5-4 
73. Sweeney MD, Ayyadurai S, Zlokovic BV. Pericytes of the neurovascular unit: 
key functions and signaling pathways. Nat Neurosci (2016) 19(6):771–83. 
doi:10.1038/nn.4288 
74. He J, Stram DO, Kolonel LN, Henderson BE, Le Marchand L, Haiman CA. The 
association of diabetes with colorectal cancer risk: the Multiethnic Cohort. 
Br J Cancer (2010) 103(1):120–6. doi:10.1038/sj.bjc.6605721 
75. Shah MM, Erickson BK, Matin T, McGwin G Jr, Martin JY, Daily LB, et al. 
Diabetes mellitus and ovarian cancer: more complex than just increasing risk. 
Gynecol Oncol (2014) 135(2):273–7. doi:10.1016/j.ygyno.2014.09.004 
8Sfera et al. Antipsychotics, Metabolic Disorders, Cerebrovascular Accidents, and miR-29
Frontiers in Endocrinology | www.frontiersin.org August 2016 | Volume 7 | Article 122
76. Hemminki K, Houlston R, Sundquist J, Sundquist K, Shu X. Co-morbidity 
between early-onset leukemia and type 1 diabetes – suggestive of a shared 
viral etiology? PLoS One (2012) 7(6):e39523. doi:10.1371/journal.pone. 
0039523 
77. Volmar CH, Wahlestedt C. Histone deacetylases (HDACs) and brain function. 
Neuroepigenetics (2015) 1:20–7. doi:10.1016/j.nepig.2014.10.002 
78. Kurita M, Holloway T, García-Bea A, Kozlenkov A, Friedman AK, Moreno JL, 
et  al. HDAC2 regulates atypical antipsychotic responses through the mod-
ulation of mGlu2 promoter activity. Nat Neurosci (2012) 15(9):1245–54. 
doi:10.1038/nn.3181 
79. Yan B, Guo Q, Fu FJ, Wang Z, Yin Z, Wei YB, et al. The role of miR-29b in can-
cer: regulation, function, and signaling. Onco Targets Ther (2015) 8:539–48. 
doi:10.2147/OTT.S75899 
80. Yang Z, Wu L, Zhu X, Xu J, Jin R, Li G, et al. MiR-29a modulates the angiogenic 
properties of human endothelial cells. Biochem Biophys Res Commun (2013) 
434(1):143–9. doi:10.1016/j.bbrc.2013.03.054 
81. Gu XS, Wang ZB, Ye Z, Lei JP, Li L, Su DF, et  al. Resveratrol, an activator 
of SIRT1, upregulates AMPK and improves cardiac function in heart failure. 
Genet Mol Res (2014) 13(1):323–35. doi:10.4238/2014.January.17.17 
82. Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, et al. Small 
molecule activators of SIRT1 as therapeutics for the treatment of type 2 
diabetes. Nature (2007) 450(7170):712–6. doi:10.1038/nature06261 
83. Mitchell SJ, Martin-Montalvo A, Mercken EM, Palacios HH, Ward TM, 
Abulwerdi G, et  al. The SIRT1 activator SRT1720 extends lifespan and 
improves health of mice fed a standard diet. Cell Rep (2014) 6(5):836–43. 
doi:10.1016/j.celrep.2014.01.031 
84. Tyagi S, Gupta P, Saini AS, Kaushal C, Sharma S. The peroxisome 
 proliferator-activated receptor: a family of nuclear receptors role in 
various diseases. J Adv Pharmaceut Technol Res (2011) 2(4):236–40. 
doi:10.4103/2231-4040.90879 
85. Tsai MJ, Wang TN, Lin YS, Kuo PL, Hsu YL, Huang MS. Aryl hydrocarbon 
receptor agonists upregulate VEGF secretion from bronchial epithelial cells. 
J Mol Med (Berl) (2015) 93(11):1257–69. doi:10.1007/s00109-015-1304-0 
86. Wang L, Waltenberger B, Pferschy-Wenzig EM, Blunder M, Liu X, Malainer 
C, et  al. Natural product agonists of peroxisome proliferator-activated 
receptor gamma (PPARγ): a review. Biochem Pharmacol (2014) 92(1):73–89. 
doi:10.1016/j.bcp.2014.07.018 
87. Buendia I, Gómez-Rangel V, González-Lafuente L, Parada E, León R, 
Gameiro  I, et  al. Neuroprotective mechanism of the novel melatonin 
derivative Neu-P11 in brain ischemia related models. Neuropharmacology 
(2015) 99:187–95. doi:10.1016/j.neuropharm.2015.07.014 
88. Zhu HQ, li Q, Dong LY, Zhou Q, Wang H, Wang Y. MicroRNA-29b promotes 
high-fat diet-stimulated endothelial permeability and apoptosis in apoE 
knock-out mice by down-regulating MT1 expression. Int J Cardiol (2014) 
176(3):764–70. doi:10.1016/j.ijcard.2014.07.095 
89. Feliciano DM, Bordey A, Bonfanti L. Noncanonical sites of adult neurogenesis 
in the mammalian brain. Cold Spring Harb Perspect Biol (2015) 7(10):a018846. 
doi:10.1101/cshperspect.a018846 
90. Schoenfeld TJ, Cameron HA. Adult neurogenesis and mental illness. 
Neuropsychopharmacol Rev (2015) 40:113–28. doi:10.1038/npp.2014.230 
91. Saharan S, Jhaveri DJ, Bartlett PF. SIRT1 regulates the neurogenic potential 
of neural precursors in the adult subventricular zone and hippocampus. 
J Neurosci Res (2013) 91(5):642–59. doi:10.1002/jnr.23199 
92. Ramos-Rodriguez JJ, Molina-Gil S, Ortiz-Barajas O, Jimenez-Palomares M, 
Perdomo G, Cozar-Castellano I, et al. Central proliferation and neurogenesis 
is impaired in type 2 diabetes and prediabetes animal models. PLoS One 
(2014) 9(2):e89229. doi:10.1371/journal.pone.0089229 
93. Ho N, Sommers MS, Lucki I. Effects of diabetes on hippocampal neuro-
genesis: links to cognition and depression. Neurosci Biobehav Rev (2013) 
37(8):1346–62. doi:10.1016/j.neubiorev.2013.03.010 
94. Ng F, Wijaya L, Tang BL. SIRT1 in the brain-connections with  aging-associated 
disorders and lifespan. Front Cell Neurosci (2015) 9:64. doi:10.3389/
fncel.2015.00064 
95. Ribe AR, Laursen TM, Charles M, Katon W, Fenger-Grøn M, Davydow D, 
et  al. Long-term risk of dementia in persons with schizophrenia: a Danish 
population-based cohort study. JAMA Psychiatry (2015) 72(11):1095–101. 
doi:10.1001/jamapsychiatry.2015.1546 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 Sfera, Osorio, Inderias and Cummings. This is an open-access 
article distributed under the terms of the Creative Commons Attribution License (CC 
BY). The use, distribution or reproduction in other forums is permitted, provided the 
original author(s) or licensor are credited and that the original publication in this 
journal is cited, in accordance with accepted academic practice. No use, distribution 
or reproduction is permitted which does not comply with these terms.
